<DOC>
	<DOCNO>NCT02993159</DOCNO>
	<brief_summary>This randomized phase IIB trial study well tamoxifen afimoxifene work treat patient estrogen receptor positive breast cancer . Estrogen cause growth breast cancer cell . Hormone therapy use tamoxifen citrate afimoxifene may fight breast cancer block use estrogen tumor cell .</brief_summary>
	<brief_title>Tamoxifen Citrate Afimoxifene Treating Patients With Estrogen Receptor Positive Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To demonstrate 2 mg daily per breast 4-hydroxytamoxifen ( 4-OHT ) topical gel result reduction Ki-67 labeling index ductal breast carcinoma situ ( DCIS ) lesion inferior see 20 mg daily oral tamoxifen citrate ( TAM ) 26 +/- 2 week , compare base-line diagnostic core biopsy therapeutic surgical excision sample . SECONDARY OBJECTIVES : I . To compare post-therapy change oncotype DCIS-score arm ( validated reverse transcriptase-polymerase chain reaction [ RT-PCR ] assay Ki67 , STK15 , survivin , cyclin B1 , MYBL2 , PR , GSTM1 ) . II . To compare between-group post-therapy change immunohistochemistry ( IHC ) marker : CD-68 macrophage marker surrogate response therapy , p16 COX-2 . III . To compare post-therapy change breast density , quantitative estimate , arm . IV . To compare post-therapy breast tissue plasma level TAM metabolite ( N-desmethyl tamoxifen [ NDT ] , [ E ] [ Z ] isomer 4-hydroxytamoxifen [ 4-OHT ] , N-desmethyl-4-hydroxytamoxifen [ endoxifen ] ) . V. To compare post-therapy breast tissue plasma level estradiol progesterone arm ( optional ) . VI . To compare post-therapy fraction participant demonstrate `` residual DCIS '' . VII . To compare post-therapy change plasma protein involve coagulation : factor VIII IX , von Willebrand factor , total protein S arm . VIII . To compare post-therapy change plasma marker systemic estrogenic effect ( IGF-1 , SHBG ) . IX . To compare post-therapy change symptom capture breast cancer prevention trial ( BCPT ) Eight Symptom Scale ( BESS ) questionnaire skin reaction 4-OHT gel . OUTLINE : Patients randomize 1 2 arm . ARM I : Patients apply afimoxifene gel breast receive placebo orally ( PO ) daily 26 week absence disease progression unexpected toxicity . ARM II : Patients apply placebo gel breast receive tamoxifen citrate orally PO daily 26 week absence disease progression unexpected toxicity . After completion study treatment , patient follow 1-2 week 1 month surgery .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Carcinoma , Ductal , Breast</mesh_term>
	<mesh_term>Carcinoma , Intraductal , Noninfiltrating</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Afimoxifene</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>Screendetected , estrogen receptor ( ER ) positive DCIS breast proven core needle biopsy , define 10 % positive cell ; presence focus suspicious microinvasion allow ; size DCIS core biopsy sample must total 5 mm ( multiple core sum ) must estimate deep step section ( step section take ) ; size lesion mammogram must &gt; = 5 mm Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 1 ( Karnofsky &gt; = 70 % ) Leukocytes &gt; = 3,000/microliter Absolute neutrophil count &gt; = 1,500/microliter Platelets &gt; = 100,000/microliter Total bilirubin within normal institutional limit Aspartate aminotransferase ( AST ) ( serum glutamicoxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) = &lt; 1.5 x institutional upper limit normal ( ULN ) Creatinine within normal institutional limit Women childbearing potential male partner must agree use TWO effective form birth control ( abstinence allow method ) prior study entry duration study participation , two month follow last dose study medication ; effective birth control method : copper IUD [ intrauterine device ] , diaphragm/cervical cap/shield , spermicide , contraceptive sponge , condom ; woman childbearing potential must negative urine pregnancy test within seven day start study medication ; woman become pregnant suspect pregnant participating study , inform study physician immediately Willingness avoid expose breast skin natural artificial sunlight ( i.e . tan bed ) duration study Ability understand willingness sign write informed consent document DCIS presentation palpable mass Exogenous sex steroid use within 4 week prior core needle biopsy Prior ipsilateral breast cancer radiotherapy exclude ; prior contralateral breast cancer therapy within 2 year also exclude Skin lesion breast disrupt stratum corneum ( eg eczema , ulceration ) History endometrial neoplasia History thromboembolic disease ( history varicose vein superficial phlebitis allow ) Current smoker Current user potent inhibitor tamoxifen metabolism must able discontinue use switch alternative medication duration participation , advice physician ; physician feel alternative medication appropriate subject current medication medically necessary , subject eligible ; drug list ; many clinical use moment ; bupropion , celecoxib , chlorpheniramine , chlorpromazine , cimetidine , citalopram , clemastine , clomipramine , clozapine , cocaine , delavirdine , desipramine , diphenhydramine , doxepin , duloxetine , escitalopram , fluoxetine , haloperidol , halofantrine , hydroxyzine , imipramine , isoniazid , ketoconazole , methadone , methimazole , mibefradil , miconazole , nicardipine , paroxetine , pergolide , perphenazine , pioglitazone , pyrimethamine , quinidine , quinine , ranitidine , ritonavir , ropinirole , sertraline , terbinafine , thioridazine , ticlopidine , tranylcypromine , trazodone , tripelennamine Prior use selective estrogen receptor modulator ( SERMS ) aromatase inhibitor ( AIs ) prevention therapy within 5 year Participants may receive investigational agent within 30 day enrollment study History allergic reaction attribute tamoxifen compound similar chemical biologic composition Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Pregnant woman exclude study ; breastfeed discontinue nursing mother agree participate study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>